Recent Pfizer Press Releases

Committee votes 6-1 that MYLOTARG in combination with chemotherapy has a favorable risk:benefit profile for patients with newly-diagnosed CD33-positive AML

Builds on 15-year history in Missouri

Supported by local and state incentives, anticipated job growth

An estimated 10 to 30 percent of pregnant women carry the GBS bacteria;¹ the vaccine candidate is being studied to help protect newborns from infection via maternal immunization

Partnership with Basilea Reaffirms Pfizer’s Global Infectious Disease Commitment and Industry Leadership

• Global Phase 3 program is studying potential new treatment option for millions of people living with chronic pain associated with osteoarthritis and chronic low back pain
• Acts in a different manner than opioids and other analgesics

- Amendment accelerates anticipated PROSPER top-line results by two years -

- Target sample size reduced to approximately 1,440 patients and estimated primary completion date is June 2017 -

— Tafamidis, An Investigational Medicine for TTR-CM a Rare, Progressive and Fatal Disease, is Currently in Phase 3 Development —

Applications seek to expand approved use of SUTENT based on data from the Phase 3 S-TRAC trial